Evidence map›Paper›PMID 26131015›Full record

ReviewAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2015

CSACI position statement: epinephrine auto-injectors and children < 15 kg.

Michelle Halbrich, Douglas P Mack, Stuart Carr, Wade Watson, Harold Kim

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 26 citations in OpenAlex.

  1. Needle-to-bone safety margin of adrenaline auto-injectors in Japanese children: Impact of injection site variation.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026
    Article
  2. Immunoglobulin E (IgE)-mediated food allergy.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024
    Review
  3. International recommendations on epinephrine auto-injector doses often differ from standard weight-based guidance: a review and clinical proposals.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022
    Review
  4. CSACI position statement: transition recommendations on existing epinephrine autoinjectors.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2021
    Article
  5. [Paediatric Life Support].Notfall & rettungsmedizin · 2021
    Review
  6. A systematic review of epinephrine stability and sterility with storage in a syringe.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2019
    Article
  7. Observational
  8. Anaphylaxis in children.Current opinion in pediatrics · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Michelle HalbrichPaediatric Allergy, Asthma and Clinical Immunology, Winnipeg Clinic, University of Manitoba, Winnipeg, MB Canada.
Douglas P MackDepartment of Pediatrics, McMaster University, Pediatric Allergy, Asthma and Immunology, Assistant Clinical Professor, McMaster University, Joseph Brant Memorial Hospital, Burlington, ON Canada.
Stuart CarrDepartment of Pediatrics, University of Alberta, Edmonton, AB Canada.
Wade WatsonDepartment of Pediatrics, Dalhousie University, Head, Division of Allergy, IWK Health Centre, Halifax, NS Canada.
Harold KimWestern University, London, ON Canada ; McMaster University, Hamilton, ON Canada.
Dalhousie University · CAMcMaster University · CAUniversity of Alberta · CAUniversity of Manitoba · CAWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epinephrine (adrenaline) is the treatment of choice for anaphylaxis. While other medications, including H1-antihistamines, H2-antihistamines, corticosteroids, and inhaled beta-2 agonists are often used to treat anaphylaxis in the emergency setting, none of these medications has been shown to reverse anaphylaxis. Fatal anaphylaxis is related to the delayed use of epinephrine. In community settings, epinephrine is available as an auto-injector in two doses, 0.15 mg and 0.3 mg. The recommended dose for children is 0.01 mg per kilogram. For infants at risk of anaphylaxis in the community, there are few options with regard to providing an optimal epinephrine dose for first-aid treatment. The Canadian Society of Allergy and Immunology (CSACI) therefore recommends, for the child weighing less than 15 kg, given the lack of a suitable alternative, prescribing the 0.15 mg epinephrine autoinjector. Adverse effects of an epinephrine dose of 0.15 mg given intramuscularly in infants or children weighing less than 15 kg are expected to be mild and transient at the plasma epinephrine concentrations achieved; therefore, these effects need to be measured against the consequences of not receiving epinephrine at all, which can include fatality.

Indexed as

AllergyAnaphylaxisCSACI position statementEpinephrineInfant

Identifiers

PMID26131015
PMCPMC4485331
OpenAlexW1605314711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.